Gabapentin Capsule
Product Images NDC 60760-740

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba (Gabapentin 60760 740 90)

Gabapentin 100 mg capsules label in a quantity of 90, labeled by St. Mary's Medical Park Pharmacy. The label includes the product name, dosage form as capsules USP, strength as 100 mg, NDC 60760-740-90, and storage instructions to store at controlled room temperature 15°-30°C (59°-86°F). The label also shows manufacturer SciGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, and the y-axis represents mean pain scores from 0 to 10. The graph highlights a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a decreasing pain score trend compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain scores over 7 weeks comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain score values from 0 to 10, with pain scores decreasing for Gabapentin groups compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) dosages. Two studies are shown: Study 1 with PBO and GBP 3600, and Study 2 with PBO, GBP 1800, and GBP 2400. The y-axis represents the percentage of responders from 0% to 100%, with GBP groups showing higher response percentages than placebo in both studies, accompanied by significance markers (** p < 0.01, *** p < 0.001).*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula includes variables such as age, weight, serum creatinine, and a factor for female patients (0.85).*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin shown as a molecular diagram with a cyclohexane ring attached to an amine group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot chart showing the percentage difference on the y-axis versus daily dose in mg on the x-axis for Gabapentin across three studies labeled a, b, and c, with data points at approximately 600, 900, 1200, and 1800 mg doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.